Search Results

Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, announces a scientific presentation at the 2023 Association for Research in Vision and Ophthalmology annual meeting in New Orleans, LA.

Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, today provided highlights from the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference held in Denver, Colorado.

Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases today announced that the company will be presenting preclinical data on its two lead candidates for geographic atrophy (GA) and wet AMD at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting.

Eyevensys today announces it has entered into strategic engagements with US-based medical device manufacturers Phillips-Medisize and Minnetronix Medical to develop the next generation of the company’s core technology.

Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, announces it has raised $12M in a Series B Plus funding round.

Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, today announced it has been accepted into the French Tech 120 program for 2021.

Eyevensys announced the expansion of its leadership team with the appointment of Gerald Cagle as the Board’s Chairman, Francine Behar-Cohen to Chief Innovation Officer and Thierry Bordet as the Chief Scientific Officer.

Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, announced the U.S. Food and Drug Administration has granted an orphan-drug designation for EYS611 for the treatment of retinitis pigmentosa.

Eyevensys, a privately held clinical-stage biotechnology company developing non-viral gene therapies for retinal and other ophthalmic diseases, announced today that it has completed a $30 million Series B financing.

Dr. Zilliox, who joined the Eyevensys board in May 2016, has more than 25 years of global clinical development expertise.